TPO and myelodysplastic syndrome: Romiplostim (ROM) and Eltrombopag (EPAG) are thrombopoietin receptor agonists (TPO-RA) [15–17], which both have already demonstrated clinical efficacy in treating MDS patients with thrombocytopenia [18–22].